Cargando…

Targeted multiomics in childhood-onset SLE reveal distinct biological phenotypes associated with disease activity: results from an explorative study

OBJECTIVE: To combine targeted transcriptomic and proteomic data in an unsupervised hierarchical clustering method to stratify patients with childhood-onset SLE (cSLE) into similar biological phenotypes, and study the immunological cellular landscape that characterises the clusters. METHODS: Targete...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wahadat, Mohamed Javad, van Tilburg, Sander J, Mueller, Yvonne M, de Wit, Harm, Van Helden-Meeuwsen, Cornelia G, Langerak, Anton W, Gruijters, Marike J, Mubarak, Amani, Verkaaik, Marleen, Katsikis, Peter D, Versnel, Marjan A, Kamphuis, Sylvia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2023
Materias:	Childhood Lupus
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10083882/ https://www.ncbi.nlm.nih.gov/pubmed/37012057 http://dx.doi.org/10.1136/lupus-2022-000799

Ejemplares similares

Usefulness of the lupus low disease activity state as a treatment target in childhood-onset SLE
por: Cody, Ellen M, et al.
Publicado: (2023)

Treatment patterns in paediatric and adult patients with SLE: a retrospective claims database study in the USA
por: Brunner, Hermine I, et al.
Publicado: (2023)

Elevated serum complement levels and higher gene copy number of complement C4B are associated with hypertension and effective response to statin therapy in childhood-onset systemic lupus erythematosus (SLE)
por: Mulvihill, Evan, et al.
Publicado: (2019)

Nailfold capillary scleroderma pattern may be associated with disease damage in childhood-onset systemic lupus erythematosus: important lessons from longitudinal follow-up
por: Schonenberg-Meinema, Dieneke, et al.
Publicado: (2022)

LLDAS is an attainable treat-to-target goal in childhood-onset SLE
por: Wahadat, Mohamed Javad, et al.
Publicado: (2021)

Analysis of relationships between 25-hydroxyvitamin D, parathyroid hormone and cathelicidin with inflammation and cardiovascular risk in subjects with paediatric systemic lupus erythematosus: an Atherosclerosis Prevention in Paediatric Lupus Erythematosus (APPLE) study
por: Gupta, Varsha, et al.
Publicado: (2018)

Validation of the Cutaneous Lupus Erythematosus Disease Area and Severity Index and pSkindex27 for use in childhood-onset systemic lupus erythematosus
por: AlE'ed, Ashwaq, et al.
Publicado: (2018)

Formal neurocognitive function and anti-N-methyl-D-aspartate receptor antibodies in paediatric lupus
por: Nowling, Tamara K, et al.
Publicado: (2021)

“There’s so much to be done”: a qualitative study to elucidate research priorities in childhood-onset systemic lupus erythematosus
por: Cannon, Laura, et al.
Publicado: (2022)

Clinical measurement of lupus nephritis activity is inferior to biomarker-based activity assessment using the renal activity index for lupus nephritis in childhood-onset systemic lupus erythematosus
por: Aljaberi, Najla, et al.
Publicado: (2022)

Pharmacokinetics of hydroxychloroquine in paediatric lupus: data from a novel, direct-to-family clinical trial
por: Balevic, Stephen J, et al.
Publicado: (2022)

Autoantibody-based subgroups and longitudinal seroconversion in juvenile-onset systemic lupus erythematosus
por: Bao, Shengfang, et al.
Publicado: (2023)

Serum IFNα2 levels are associated with disease activity and outperform IFN-I gene signature in a longitudinal childhood-onset SLE cohort
por: Wahadat, M Javad, et al.
Publicado: (2022)

Gene signature fingerprints stratify SLE patients in groups with similar biological disease profiles: a multicentre longitudinal study
por: Wahadat, M Javad, et al.
Publicado: (2022)

Performance of the proposed ACR–EULAR classification criteria for systemic lupus erythematosus (SLE) in a cohort of patients with SLE with neuropsychiatric symptoms
por: Gegenava, Maka, et al.
Publicado: (2019)

Leucocyte subset-specific type 1 interferon signatures in SLE and other immune-mediated diseases
por: Flint, Shaun M, et al.
Publicado: (2016)

Immunogenicity, safety and reactogenicity of a heterogeneous booster following the CoronaVac inactivated SARS-CoV-2 vaccine in patients with SLE: a case series
por: Assawasaksakul, Theerada, et al.
Publicado: (2021)

Standardised incidence ratios (SIRs) for cancer after renal transplant in systemic lupus erythematosus (SLE) and non-SLE recipients
por: Ramsey-Goldman, Rosalind, et al.
Publicado: (2016)

Type I IFN signature in childhood-onset systemic lupus erythematosus: a conspiracy of DNA- and RNA-sensing receptors?
por: Wahadat, M. Javad, et al.
Publicado: (2018)

p16(Ink4a), a marker of cellular senescence, is associated with renal disease in the B6.NZMSle1/Sle2/Sle3 mouse model of lupus
por: Tilman, Gaëlle, et al.
Publicado: (2023)

What to Expect When Expecting With Systemic Lupus Erythematosus (SLE): A Population‐Based Study of Maternal and Fetal Outcomes in SLE and Pre‐SLE
por: Arkema, Elizabeth V., et al.
Publicado: (2016)

Genotype-guided new approach for dose optimisation of hydroxychloroquine administration in Chinese patients with SLE
por: Xie, Han, et al.
Publicado: (2023)

Time to onset of clinical response to anifrolumab in patients with SLE: pooled data from the phase III TULIP-1 and TULIP-2 trials
por: Bruce, Ian N, et al.
Publicado: (2023)

Mer-tyrosine kinase: a novel susceptibility gene for SLE related end-stage renal disease
por: Yavuz, Sule, et al.
Publicado: (2022)

Safety, pharmacokinetics and pharmacodynamics of AMG 811, an anti-interferon-γ monoclonal antibody, in SLE subjects without or with lupus nephritis
por: Boedigheimer, Michael J, et al.
Publicado: (2017)

Microvascular C5b-9 deposition in non-lesional skin in patients with SLE and its correlation with active lupus nephritis: a prospective observational study
por: Anderson, Meghan, et al.
Publicado: (2023)

Safety of procuring research tissue during a clinically indicated kidney biopsy from patients with lupus: data from the Accelerating Medicines Partnership RA/SLE Network
por: Deonaraine, Kristina K, et al.
Publicado: (2021)

White matter hyperintensities associate with cognitive slowing in patients with systemic lupus erythematosus and neuropsychiatric symptoms
por: Monahan, Rory Caitlin, et al.
Publicado: (2021)

Autoantibodies against specific post-translationally modified proteins are present in patients with lupus and associate with major neuropsychiatric manifestations
por: Monahan, Rory C, et al.
Publicado: (2022)

Influence of renal complications on the efficacy and adverse events of tacrolimus combination therapy in patients with systemic lupus erythematosus (SLE) during a maintenance phase: a single-centre, prospective study
por: Ishii, Sho, et al.
Publicado: (2015)

Systemic lupus erythematosus: state of the art on clinical practice guidelines
por: Tamirou, Farah, et al.
Publicado: (2019)

Combined genetic and transcriptome analysis of patients with SLE: distinct, targetable signatures for susceptibility and severity
por: Panousis, Nikolaos I, et al.
Publicado: (2019)

Extranodal marginal zone lymphoma clonotypes are detectable prior to eMZL diagnosis in tissue biopsies and peripheral blood of Sjögren’s syndrome patients through immunogenetics
por: Kolijn, P. Martijn, et al.
Publicado: (2023)

Stroke in systemic lupus erythematosus: a meta-analysis of population-based cohort studies
por: Holmqvist, Marie, et al.
Publicado: (2015)

Role of P-glycoprotein on CD69(+)CD4(+) cells in the pathogenesis of proliferative lupus nephritis and non-responsiveness to immunosuppressive therapy
por: Tsujimura, Shizuyo, et al.
Publicado: (2017)

Endothelial dysfunction is associated with activation of the type I interferon system and platelets in patients with systemic lupus erythematosus
por: Tydén, Helena, et al.
Publicado: (2017)

Environmental and lifestyle factors influencing risk of congenital heart block during pregnancy in anti-Ro/SSA-positive women
por: Meisgen, Sabrina, et al.
Publicado: (2017)

Glucocorticoid withdrawal in systemic lupus erythematosus: are remission and low disease activity reliable starting points for stopping treatment? A real-life experience
por: Tani, Chiara, et al.
Publicado: (2019)

Therapeutic implications of the anergic/postactivated status of B cells in systemic lupus erythematosus
por: Dörner, Thomas, et al.
Publicado: (2020)

Management of lupus nephritis: a systematic literature review informing the 2019 update of the joint EULAR and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations
por: Kostopoulou, Myrto, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_sdjr6eukd8t66m905453s45mak